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Abstract
Background: Protein distribution profiles along the human intestinal tract of transporters involved in the absorption of
cholesterol and long-chain fatty acids (LCFA) have been scarcely evaluated.
Methodology/Principal Findings: In post-mortem samples from 11 subjects, intestinal transporter distribution profiles were
determined via Western Blot. Differences in transporter protein levels were statistically tested using ANOVA and Tukey’s
Post Hoc comparisons. Levels in all segments were expressed relative to those in duodenum. Except for ABCG5 and FATP4,
levels (mean6SEM) were the highest in the ileum. For ABCA1, ileal levels (1.8060.26) differed significantly from those in
duodenum (P=0.049) and proximal colon (0.9260.14; P=0.029). ABCG8 levels in ileum (1.9160.30) differed from those in
duodenum (P=0.041) and distal colon (0.8460.22; P=0.010) and jejunum (1.6460.26) tended to be higher than distal colon
(0.8460.22; P=0.087). Ileal NPC1L1 levels (2.5660.51) differed from duodenum levels (P=0.019) and from distal colon
(1.0960.22; P=0.030). There was also a trend (P=0.098) for higher jejunal (2.2360.37) than duodenal NPC1L1 levels. The
levels of ABCG5 did not correlate with those of ABCG8. FAT/CD36 levels in ileum (2.0360.42) differed from those in
duodenum (P=0.017), and proximal and distal colon (0.8960.13 and 0.9760.15 respectively; P=0.011 and P=0.014).
FABPpm levels in ileum (1.0460.13) differed from proximal (0.6460.07; P=0.026) and distal colon (0.6660.09; P=0.037).
Conclusions/Significance: The distribution profiles showed a bell-shape pattern along the GI-tract with the highest levels in
ileum for ABCA1, ABCG8, NPC1L1, FATCD36 and FABPm, suggesting a prominent role for ileum in transporter-mediated
uptake of cholesterol and LCFAs.
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Introduction
The incidence of the metabolic syndrome (MS) has rapidly
increased over the last few decades [1,2]. MS is a clustering of
metabolic risk markers, including abdominal obesity, elevated
plasma glucose levels, and an atherogenic lipid profile, which
altogether contribute to the development of cardiovascular disease
(CVD) [3,4]. Patients suffering from the MS often show
disturbances in fatty acid (FA) metabolism [5] leading to elevated
plasma free fatty acid levels which negatively influence insulin-
mediated glucose uptake [6,7]. The disturbances in lipoprotein
profiles most likely originate from an elevated hepatic production
of large triacylglycerol-rich VLDL1 particles, which in combina-
tion with increased cholesterylester transfer protein (CETP)
mediated lipid fluxes and decreased lipoprotein lipase (LPL)
mediated lipolysis results in hypertriglyceridemia and low serum
HDL cholesterol concentration [8,9,10]. However, it becomes
more and more evident that lipoprotein metabolism is also
regulated by absorption characteristics of cholesterol and FA in the
intestine. For example, it was recently shown that the level of
cholesterol absorption from the intestine was inversely related to
reverse cholesterol transport from peripheral tissue macrophages
into the feces [11].
Concerning the MS, there is an ongoing discussion whether these
patients are characterized by elevated and/or accelerated intestinal
cholesterol absorption or not. In this respect, Miettinen et al.[ 1 2 ]
have proposed, that subjects can be characterized as cholesterol
absorbers (with a low cholesterol synthesis) or as cholesterol
synthesizers (with a low cholesterol absorption). Based on circulating
levels of plant sterols which can be used as markers for fractional
cholesterol absorption, it has been suggested that subjects with the
MS are rather cholesterol synthesizers than absorbers [13]. Indeed,
obese subjects displayed increased cholesterol synthesis and a
decreased fractional cholesterol absorption [14].
Intestinal cholesterol absorption is tightly regulated by a number
of transporter proteins and whether an individual is a cholesterol
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10380absorber or cholesterol synthesizer might be influenced by
variations in the intestinal protein levels or activities of these
cholesterol transporters. Four important proteins involved in
transporting sterols across the intestinal lining are (1) adenosine-
triphosphate (ATP) binding cassette A1 (ABCA1), a 226 kDa
basolateral membrane protein which is involved in the synthesis of
HDL by basolateral donation of cholesterol to its acceptor
apolipoprotein A1; (2) ATP binding cassette G5 (ABCG5) and
(3) G8 (ABCG8), also called sterolin-1 and sterolin-2 respectively,
both with a molecular weight of ,65 kDa. ABCG5 and ABCG8
are expressed apically at the brush border membrane [15] and
collaborate in transporting excess sterols out of the enterocyte back
into the lumen [16]. The fourth protein is Niemann-Pick C1 like 1
(NPC1L1), a 150 kDa protein which may cooperate with the
scavenger receptor class B type 1 (SR-BI) [17] and regulates the
intestinal uptake of sterols (figure 1). In addition, some recent
studies suggest that several FA transporters, i.e. membrane fatty
acid translocase (FAT/CD36) and cytoplasmic fatty acid-binding
protein (I-FABP and L-FABP), are also involved in the uptake of
cholesterol, making cholesterol and long-chain fatty acid (LCFA)
uptake potentially interrelated [18,19,20].
Important intestinal FA transporters are (1) FABPpm, a 40 kDa
protein located peripherally on the plasma membrane and
identical to the mitochondrial enzyme aspartate aminotransferase
[21]; (2) FAT/CD36, an 88 kDa integral membrane glycoprotein
with two predicted transmembrane domains, also known as the
Class B scavenger receptor CD36 [22] and (3) fatty acid transport
protein subtype 4 (FATP4), a 63 kDa integral membrane protein
which possibly can drive fatty acid uptake or activate FA by
trapping them inside the cell as their CoA thioesters
[23,24,25,26,27]. Once LCFA are taken up, they can be
transported to the mitochondria via cytoplasmic fatty acid-binding
proteins (FABPc) for b-oxidation (figure 2) [28,29]. These proteins
also facilitate the cellular uptake of FA and protect against the
cytotoxic effects of free cellular FA [30].
Data concerning differences in the intestinal levels of these
transporter proteins between MS patients and healthy controls is
not available. However, new strategies to improve serum
lipoprotein profiles could focus on the role of the intestine in
dyslipidemia [31,32]. Therefore, it is important to know the
intestinal protein distribution profiles of these transporter proteins
in order to develop possible site-specific modulators of intestinal
Figure 1. Intestinal uptake of dietary cholesterol. Dietary cholesterol (ch) and plant sterols/stanols (ps) travel, incorporated in mixed micelles,
through the intestinal lumen. The sterols are transported across the brush-border membrane by NPC1L1. Once taken up, sterols are either
incorporated in apoB48-rich chylomicrons (CM), which are secreted in the lymph compartment, or used to form apoA1-rich HDL cholesterol, a
process that is mediated by ABCA1. Excess amounts of sterols are also excreted into the intestinal lumen by the reverse sterol transporters ABCG5
and G8. The level of transport proteins is under tight control of the liver X receptor (LXR) gene. This gene indirectly measures cellular sterol levels and
regulates the transcription of sterol transporters NPC1L1, ABCA1, ABCG5 and G8.
doi:10.1371/journal.pone.0010380.g001
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investigate the protein levels of the above-mentioned transporters
which were chosen based upon recent up-to-date reviews, in
different segments of the intestinal tract to visualize their
distribution profiles along the human duodenal-colonal axis.
Results
(Chole)sterol transport proteins
As explained in the method section, the level of each individual
protein in duodenum was arbitrarily set at 1. ABCA1 protein level
was significantly higher in ileum (1.8060.26) than in duodenum
(P=0.049) and proximal colon (0.9260.14; P=0.029) (figure 3A).
For ABCG5, no significant differences between duodenum,
jejunum (1.4160.19), ileum (1.1360.20), proximal colon
(0.9860.24) and distal colon (0.9860.19) were found (figure 3B).
Ileal level of ABCG8 was significantly higher (1.9160.30) than
that in duodenum (P=0.041) and distal colon (0.8460.22;
P=0.010) and also tended to be higher in jejunum (1.6460.26)
than in distal colon (P=0.087) (figure 3C). The protein level of the
cholesterol transporter Niemann-Pick C1 Like 1 was significantly
higher in ileum (2.5660.51) as compared to that in duodenum
(P=0.019) and in distal colon (1.0960.22; P=0.030), whereas
jejunum NPC1L1 level (2.2360.37) tended to be higher than
distal colon (P=0.098). (figure 3D). Blots of individual subjects
representative for the group are presented in figure 3E. Protein
levels of the various sterol transporters did not differ between men
and women, and did not correlate with age. There was no
significant correlation between ABCG5 and ABCG8.
Concerning possible influence of protein degradation in the
samples, linear regression analysis between time of biopsy after
death and expression levels of ABCA1, ABCG8, NPC1L1 and
FAT/CD36 did not show any association, whereas even a positive
relation was found for ABCG5 (R
2=0.25; P=0.0001). Addition-
ally, this analysis was performed per intestinal segment, but the
results were comparable (data not shown).
Long-chain fatty acid transport proteins
FABPpm protein level was significantly higher in ileum
(1.0460.13) than in proximal colon (0.6460.07; P=0.026) and
distal colon (0.6660.09; P=0.037), and tended to be higher in
duodenum than in proximal and distal colon (P=0.059 and
P=0.082 respectively) (figure 4A). For FATP4, no significant
differences were found between any of the segments (figure 4B).
FAT/CD36 protein level was significantly higher in ileum
(2.0360.42), when compared to that in duodenum (P=0.017),
proximal colon (0.8960.13; P=0.011) and distal colon
(0.9760.15; P=0.014) (figure 4C). Comparable to the sterol
transporters, no significant differences were found in intestinal
LCFA transporter levels between men and women and no
correlations with age could be shown. Blots of individual subjects
representative for the group are presented in figure 4D.
Figure 2. Intestinal uptake of dietary fatty acids. Dietary fatty acids (FA) pass through the intestinal lumen whilst esterified to triacylglycerols
(TAG) or incorporated into mixed micelles. Gastric and hepatic lipases free the fatty acids, which are then receptive to uptake. Fatty acids are either
transported across the apical membrane actively by FATP4, FAT/CD36 or FABPpm, or passively diffuse (blocked arrows) through the lipid bilayer. In
the enterocyte FABPc facilitates fatty acid transport through the cytosol. In the cytoplasm, the major part of fatty acids is re-esterified to
triacylglycerols and excreted into chylomicrons (CM), whereas a small part is excreted as free fatty acids (FFA).
doi:10.1371/journal.pone.0010380.g002
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Sterol transporters
Since intestinal cholesterol absorption is tightly regulated by a
number of transporter proteins (ABCA1, ABCG5, ABCG8, and
NPC1L1) we decided to describe for the first time distribution
profiles of these transporter proteins along the duodenal-colonic
axis in humans, as a first step to further understand in vivo human
intestinal cholesterol metabolism. In contrast to humans, some
animal data on the importance of different segments for intestinal
cholesterol metabolism is available. For example, Sylven et al. [33]
have reported that in rats the major part of cholesterol was taken
up in the proximal half of the small intestine, when cholesterol was
administered in crystallized form. When administered in an oil
phase, the gross uptake occurred more distally. In humans,
cholesterol is first incorporated into micelles in the duodenum.
Thus, if these animal data can be extrapolated to the human
situation, it suggests that cholesterol absorption in humans mainly
occurs in the distal part of the small intestine. From another study
in 29 obese subjects undergoing Roux-en-Y gastric bypass [34], it
Figure 3. Distribution patterns of cholesterol transporter proteins along the longitudinal axis of the human intestine. These
transporter proteins included ABCA1 (panel A), ABCG5 (panel B), ABCG8 (panel C) and NPC1L1 (panel D). Panel E displays Western Blots of the
different segments of a single subject, which is representative for the average distribution pattern of ABCA1, ABCG5 and ABCG8 and NPC1L1.
*=P,0.05 compared to duodenum; #=P,0.05 compared to proximal colon; $=P,0.05 compared to distal colon. D=duodenum, J=jejunum,
I=ileum, PC=proximal colon and DC=distal colon.
doi:10.1371/journal.pone.0010380.g003
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after bypassing the proximal intestine. However, uptake of
cholesterol was not completely abolished, suggesting that the
more distal regions of the intestine are also capable of absorbing
cholesterol. On the other hand, from in vivo studies with porcine
intestine, it was concluded that the predominant site for cholesterol
uptake was the jejunum [35,36,37]. Thus, results from animal and
human studies are not uniform and it was therefore a priori
unclear in which segment the protein level of cholesterol-
transporter proteins like NPC1L1, ABCG5 and ABCG8 would
be most abundant. We now found that the levels of NPC1L1 and
ABCG8 were bell-shaped along the proximal-distal axis, with the
highest levels in ileum, suggesting that transporter-dependent
sterol fluxes in humans could be located more distally than in pigs
and rodents.
For mRNA, Davies et al. [38], showed that NPC1L1 expression
was very similar in jejunum, ileum and duodenum, but higher in
these segments than in segments of the large intestine. This may
suggest that protein levels do not parallel mRNA expression.
Another study in rats found the highest NPC1L1mRNA and
protein levels in jejunum [39]. Similarly, Sane ´ and coworkers [17]
found the highest levels of NPC1L1 protein in jejunum in human
subjects. The differences between this human study and our results
might be explained by the difference in subject population. The
samples in the study by Sane ´ et al. were partially derived from
patients with Crohn’s Disease, which are known to display
abnormalities in lipid metabolism [40,41], which presumably
might coincide with alterations in transporter expression levels and
distribution patterns. Finally, it should be realized that a lot of the
data available in the literature is derived from animal studies. In
this respect, species-specific differences in organ-specific transport
protein mRNA levels between mouse, rat and human tissue have
been shown [39]. This may be an additional reason for different
transporter distribution patterns within the intestine between
humans and other species.
Because of the co-localization of ABCG5 and ABCG8 towards
the apical membrane [42,43,44], a similar distribution pattern of
these two transporters was expected. However, ABCG5 levels
were very similar between the intestinal segments and did not
correlate with ABCG8 levels, for which we do not have an
explanation.
ABCA1 plays a role in the biogenesis of anti-atherogenic high-
density lipoproteins (HDL) in the intestinal lining [45,46,47].
Using enterocyte specific ABCA1 knock-out mice, Brunham et al.
[48] showed that in mice approximately 30% of the steady state
plasma HDL pool was due to intestinal ABCA1 activity.
According to our data, ABCA1 protein levels were the highest
in ileum. A similar distribution has been described for ABCA1
Figure 4. Distribution patterns of fatty acid transporter proteins along the longitudinal axis of the human intestine. These transporter
proteins included FABPpm (panel A), FATP4 (panel B) and FAT/CD36 (panel C). Panel D displays Western Blots of the different segments of a single
subject, which is representative for the average distribution pattern of FABPpm and FATP4. *=P,0.05 compared to duodenum; #=P,0.05
compared to proximal colon; $=P,0.05 compared to distal colon. D=duodenum, J=jejunum, I=ileum, PC=proximal colon and DC=distal colon.
doi:10.1371/journal.pone.0010380.g004
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mediated assembly of HDL in the human intestine mainly occurs
in ileum.
Except for levels (expressed per mg of total protein) of the active
transporters, the actual absorption also depends on the surface
areas of the different segments. Estimates for the duodenum are
0.1 m
2, for jejunum 60 m
2, for ileum 60 m
2, and for colon 0.2 m
2
[50,51]. Combining these areas with the segmental transporter
levels, it can now be hypothesized that the ileum is the most
important site for transporter-dependent sterol fluxes. Moreover,
based on the finding that bowel resection of the proximal 75% of
the pig small intestine led to adaptive absorption of cholesterol in
ileum [35], it is tempting to speculate that also the dietary
availability of fatty acids and cholesterol is important in
understanding these processes. Relatively, intraluminal availability
of (dietary) cholesterol and LCFA is highest in duodenum, where a
lot of fatty acids and cholesterol can easily be absorbed by the
relevant transport proteins and also passive diffusion of FA is more
eligible to occur. More distally, relative cholesterol and fatty acid
bioavailability is lower, and therefore more transport proteins are
required for the same absolute uptake of cholesterol.
Sterol and LCFA transporters
Recent studies have suggested that the LCFA transporter FAT/
CD36, like the cholesterol transporter NPC1L1 a member of the
CD36 superfamily, plays a crucial role in cholesterol uptake in the
proximal intestine of mice [18]. In FAT/CD36 deficient mice, in
vitro cholesterol uptake in the first of three equal intestinal segments
was approximately 75% lower as compared to that in wild-type
littermates. For the second and third segment no differences were
found. The distribution pattern of FAT/CD36 was comparable to
the pattern found for NPC1L1, but the highest protein expressions
were found more distally than would be expected based upon the
hypothesis of their role in proximal cholesterol uptake, however
the patterns found in this study for NPC1L1 and FAT/CD36 were
comparable.
In a different study on the role of FA transporters in cholesterol
transport [19], overexpression of cytoplasmic I-FABP in a human
intestinal epithelial cell line not only resulted in a decrease in free
cholesterol absorption from micelles, but also in a downregulation
of NPC1L1, and upregulation of ABCA1, ABCG5 and G8. These
findings suggest that overexpression of cytosolic I-FABP favors
cholesterol efflux.
Expression of transporter molecules may be changed by the
composition of the diet, as in mice the FABP protein level in the
distal small intestine was increased after high-fat intakes [52].
Similar findings were shown for FAT/CD36 after consumption of
LCFAs, but not after consumption of MCFAs [53]. These studies
clearly indicate a role for nutrition in regulating transporter
mRNA and possibly also protein levels. Unfortunately, we have no
data records on dietary habits of the subjects. De Vogel-van den
Bosch et al. [20] studied the possible interrelations between FA and
cholesterol uptake in vivo. A cholesterol-free, high-fat diet
suppressed gene expression of the cholesterol transporters
NPC1L1, ABCA1, ABCG5 and ABCG8 in the middle segment
of the mouse small intestine after 2, 4 and 8 weeks. Thus, these
studies suggest that an interrelation exists between FA and
cholesterol uptake, potentially mediated by changes in intestinal
transporter activity. Although these interrelations are not com-
pletely understood, it does suggest that knowledge on distribution
profiles of LCFA transporters in combination with those of sterol
transporters is needed to optimize potential intervention strategies
to lower sterol absorption.
Besides playing a potential role in intestinal cholesterol uptake,
FAT/CD36 is also involved in a wide range of physiological
processes and disorders [54]. FAT/CD36 in particular is
important for very long-chain (VLC) FA (more than 18 carbon
atoms) metabolism, since intestinal VLCFA uptake was completely
abolished in CD36
2/2 mice [55].
Lobo et al. [56] described that in humans, FAT/CD36 protein
was restricted to duodenal and jejunal epithelium. On the other
hand, Poirier et al. [53] also found FAT/CD36 protein in rat ileal
epithelium, although in lower amounts, with the highest FAT/
CD36 protein expression in jejunum, followed by duodenum. In
both of the studies, membrane proteins were separated from the
lysates and then further analyzed. In contrast, Chen et al. [57] used
total cell lysate, and found a distribution pattern comparable with
that of Poirier et al. [53], but also found FAT/CD36 protein in the
stomach and colon of rats. Another study by Nassir et al. [18]
found the highest levels of FAT/CD36 in rats in duodenum, with
a steep decrease in expression when proceeding more distally.
Because of the apparent discrepancies in transporter expression
profiles between species, Wang et al. [58] analyzed tissues of both
rats and humans. They used total lysates – in line with Chen et al.
[57] - and showed ubiquitous CD36 mRNA and protein in all
intestinal segments of the rat. In the human samples the mRNA
distribution was different from FAT/CD36 protein, since FAT/
CD36 protein was highest in ileum, while mRNA was lower in
ileum than in duodenum, jejunum and colon. Our data closely
resemble the protein data from Wang et al., in which the same
technique for tissue preparation was used. The above data
indicates that there are differences in the distribution patterns of
CD36 between different species and that, at least in humans,
protein levels do not resemble mRNA levels, a finding of which
there are numerous other examples as reviewed by Glatz et al.
[59]. Our results suggest a more distally situated (ileum) FAT/
CD36-mediated uptake of LCFA in humans than in rats.
Additionally, we found a small amount of FAT/CD36 in colon,
but levels were relatively low.
Concerning other fatty acid transporters, it was suggested that
FABPpm is co-expressed with FAT/CD36 [58]. Indeed, there are
several indications for an interaction between both transporters at
the protein level [60,61]. As levels were the highest in the ileum,
our results suggest that the small intestine is more important than
the large intestine in FABPpm mediated LCFA uptake. Co-
expression of FABPpm and FAT/CD36 is not suggested by our
data, since we did not find significant correlations for any of the
segments.
Also FATP4 is important in LCFA transport [23,62]. In mice,
Stahl et al. [23] showed the highest expression of FATP4 in
jejunum and ileum, but there were also detectable amounts
present in duodenum. These findings are partly confirmed by our
study, since we found FATP4 in all segments. The presence of
FATP4 in human colon is not in agreement with the findings of
Stahl et al. [23]. We suggest that the presence of fatty acid
transporters in the distal intestine is a last resort for the absorption
of LCFA. In fact, fatty acid uptake is very efficient and
approximately 90–95% of dietary fatty acids are absorbed. Most
of the FA uptake is probably complete in the proximal small
intestine [63,64], but also ileum is capable of absorbing FA
[65,66], which is in line with the locations of the LCFA transport
proteins in combination with estimations of segmental surface
area.
Gender and age differences
Duan et al. [67] showed that estrogens may influence cholesterol
uptake through up-regulation of NPC1L1 and possibly by down-
Transport Protein Patterns
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was suggested that estrogen acts as transcription modulator for the
target genes through effects on estrogen receptor (ER) a or ER b,
two subtypes of the steroid hormone receptor superfamily.
Furthermore, a significant positive effect of aging on cholesterol
uptake through inhibition of the sterol efflux transporters ABCG5
and ABCG8 has been reported [67]. In contrast, fat uptake was
suggested to decline with ageing [68,69,70] and also more recently
decreased ileal uptake of palmitic, stearic, oleic and linoleic acid
was found with ageing in rats [71]. These effects were abolished
when mucosal surface area was considered. Other studies however
have suggested that age is not related to lipid absorption [72] or to
morphological changes of the intestine [73], whilst others have
even reported an increased lipid uptake with ageing [74]. We did
not find a decrease in any of the lipid transport proteins with
ageing, nor did we find gender-related differences. However, since
the women were probably post-menopausal, no estrogen-related
gender difference was expected. Concerning the influence of
gender and age, the power of the study may not have been
sufficient or the range of age may not have been large enough.
Conclusion
In conclusion, this is the first study that has analyzed the
distribution of cholesterol and LCFA transport proteins along the
entire human duodenal-colonal axis. Protein distribution patterns
are different from the sites suggested for predominant uptake of
cholesterol and LCFA in pigs, mice and rats [18,33,35,36]. Our
expression data, combined with recent physiological in vivo
observations in humans suggest also a prominent role for more
distal parts, i.e. ileum, in transporter-mediated uptake of at least
cholesterol.
This strengthens the assumed differences in species-specific
expression patterns. Moreover, also the discrepancy between the
distribution patterns of ABCG5 and ABCG8 was not expected.
Unfortunately, we were not able to determine the subcellular
distribution of cholesterol and LCFA transporters or protein
activities. Altogether these findings indicate that further research
in this field is warranted.
Materials and Methods
Ethics Statement
The study had been approved of by the respective local medical
ethical committees.
Human tissue preparation
Human intestinal tissue samples were obtained from autopsies
of 7 female and 4 male subjects, aged 37 to 83 years (62.865.0
(mean6SEM); Medical University of Bialystok, Bialystok, Poland
and Mental Hospital, Choroszcz, Poland), 18.161.5 h after death
(table 1). The subjects died of non-intestine related diseases, such
as cardiac, cerebral, renal or pulmonary events. Samples, which
were directly frozen in liquid nitrogen, were taken from the
duodenum (10 cm from pylorus), jejunum (50 cm from pylorus),
ileum (15 cm from ileocecal junction), proximal colon (5 cm from
ileocecal junction) and distal colon (10 cm from splenic flexure).
Subsequent sample preparations were performed at 4uC.
Before analyses, tissues were homogenized (3–16% w/v) in
SET-buffer (0.25 M sucrose, 10 mM EDTA, 10 mM Tris,
pH 7.4) using an Ultra-Turrax homogenizer (IKA Werke,
Breisgau, Germany) and sonificated on ice (4615 s, MSE
ultrasonic disintegrator). Total crude homogenate samples were
stored at 280uC until analyses. Protein concentrations in the tissue
homogenates were quantified with the Pierce micro-BCA assay
(Pierce, Rockford, USA).
Western blot analyses of human FABPpm, FATP4,
ABCG5/G8, ABCA1 and NPC1L1
For detection of FABPpm, tissue samples containing 30 mg
protein were loaded on SDS-PAGE precast gels (4–15% gradient
gel, Tris-HCl, 1.0 mm, Biorad, Hercules, USA) applying the
Criterion
TM system (Biorad, Hercules, USA). For detection of
ABCG5, ABCG8 and FATP4, self-cast gels were prepared with a
7.5% gradient. For ABCA1 and NPC1L1 detection, a gel with a
gradient of 5% was prepared. Samples were electrophorezed
(90 min, 200 V) and blotted on nitrocellulose (0.45 mm) at 4uC.
After blotting, membranes were blocked overnight at 4uC with
either 5% non-fat dry-milk (NFDM) in TBS-Tween 20 0.1%
(TBS-T) for FABPpm, ABCG5, ABCG8 and FATP4, and 3%
NFDM in TBS-T for ABCA1 and NPC1L1. After blocking, all
blots were washed 5 times with TBS-T and incubated for 1 h with
the primary antibodies polyclonal goat anti-FATP4 (prepared,
purified and characterized by dr. J. Fu ¨llekrug, Department of
Gastroenterology, University Hospital Heidelberg, Germany),
polyclonal anti-ABCG5 and anti-ABCG8 (Santa Cruz Biotech-
nology, CA, USA), polyclonal rabbit anti-FABPpm (kind gift from
dr. Calles-Escandon, Department of Medicine, University of
Vermont, Burlington, Vermont), monoclonal mouse anti-ABCA1
(kind gift from dr. A.K. Groen, Department of Pediatrics/
Laboratory Medicine, University Hospital Groningen, Groningen,
The Netherlands), polyclonal rabbit anti-NPC1L1 (Cayman
Chemical, MI, USA) in either 5% non-fat dry-milk (NFDM) in
TBS-Tween 20 0.1% (TBS-T) for FABPpm, ABCG5 and G8 and
FATP4, and 3% NFDM in TBS-T for ABCA1 and NPC1L1.
Following overnight blocking, secondary antibodies were added
and incubated for 60 min. Detection of ABCG5/G8, FABPpm,
FATP4, ABCA1 and NPC1L1 was performed by enhanced
chemi-luminescence (ECL). Blots were subsequently analyzed by
Quantity One software (Biorad, Hercules, USA).
FAT/CD36 ELISA
FAT/CD36 protein level in the different segments was
measured via a sandwich ELISA as described previously [75]. In
short, a polyvinylchloride microtitre plate (Falcon type 3912,
Beckton Dickinson, Oxnard, CA) was coated overnight and
washed five times. Thereafter, wells were blocked for 30 min with
PBS/2% Marvel. Following 5 washing steps with PBT, standard
containing 0–1 mg/ml recombinant 6-His FAT in PBS/0.4%Tri-
ton X-100 was added per well. The samples were diluted 1:1 and
added to the plate after centrifugation. After incubation for
90 min, wells were washed. Then, phage (2610
11 colony forming
units (cfu)/well in PBS/2% Marvel) were added and incubated for
90 min. After 5 washes, 1/5000 diluted sheep anti-fd labeled with
horseradish peroxidase in PBS/2% Marvel was added. After one-
Table 1. Subject information on age at death and biopsy
time (mean6SEM).
men women all p
N 471 1 -
age at death 57.869.4 65.765.9 62.865.0 0.469
time of biopsy 20.062.8 17.061.7 18.161.5 0.360
doi:10.1371/journal.pone.0010380.t001
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TMB/well. The reaction was stopped after 10 min and the
absorbance was read at 450 nm using a Titertek Multiscan MkII
microplate reader. The CD36 ELISA showed a detection limit of
50 mg/L. Using standards of 2000 and 1000 mg/L, the intra-assay
and inter-assay coefficients of variation (CV) were ,10% and
15%, respectively.
Standardization
Protein level of each lane was standardized by loading 30 mgo f
protein for every sample. A duodenal biopsy sample was included
in every blot as an internal standard and levels of intestinal protein
level of all biopsy samples loaded on the blots were corrected for
the variations in the internal standards. Furthermore, duodenal
transporter level was set at 1 and levels in the other segments were
compared to that in duodenum.
Since intestinal samples contained both enterocytes and
myocytes, we also measured H-FABP as a marker of muscle
content with a direct non-competitive sandwich-type ELISA using
monoclonal antibodies obtained from Hycult biotechnology (HK
403; Uden, the Netherlands) as described previously [76]. These
data showed significantly higher H-FABP in jejunum (1.7360.30)
as compared to duodenum, ileum (1.0960.19), proximal colon
(0.9760.16) and distal colon (0.9060.17), Because of this, we
concluded that the biopsy muscle content was for an unknown
reason higher in our jejunum biopsies and this might have resulted
in an underestimation of cholesterol transport protein levels, which
are only expressed in enterocytes. Therefore cholesterol transport
protein levels were corrected for the muscle content as measured
via hFABP levels. Because FA transport proteins are also present
in myocytes, differences in distribution patterns of the fatty acid
transporters could have been influenced by the higher levels of
myocytes in our jejunal biopsies. However, it is not possible to
correct FA transporter levels for this possible confounding effect,
because of their presence in myocytes and we do not know
whether this correction might lead to overestimation or underes-
timation of the transport protein levels.
Statistical analysis
Data are presented as mean 6 SEM. All protein levels were
related to the duodenal protein level. All data were normally
distributed as tested with Shapiro-Wilk’s test for normality.
Analysis of variance (ANOVA) was used to compare mean
transporter levels between the various segments of the intestine.
Alpha inflation due to multiple comparisons was corrected with
Tukey’s HSD Post Hoc tests and P,0.05 was considered to be
statistically significant. Independent sample t-tests were used to
compare transporter levels between men and women within each
segment. Pearson’s correlations were determined to evaluate the
possible relationship between ageing and intestinal transport
protein level within each segment. Moreover, linear regression
analysis was performed regarding time of biopsy after death versus
expression levels of ABCA1, ABCG5, ABCG8, NPC1L1 and
FAT/CD36 to evaluate whether protein degradation was an issue.
All tests were performed with SPSS 16.0 (SPSS Inc. Chicago,
Illinois).
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